# Lexeo Therapeutics Inc. (LXEO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.89, market value $401 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Lexeo Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 613.5×**. Each dollar of revenue is priced at 613.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -22.1%** (5-yr avg -46.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -40.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: -22.1%**. Each dollar of assets produces -22.1% of profit.

## Growth
- **EPS growth (1 yr): 39.8%**. Earnings per share rose 39.8%.

## Financial health
- **Interest coverage: -664.9×**. Operating profit covers interest only -664.9×: fragile.
- **Current ratio: 11.21** (quick 11.21). Current assets cover the next year's liabilities 11.21 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Lexeo Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -1.6%** (YTD -50.8%, 3-mo 11.9%). The shares are down 1.6% over twelve months including dividends.
- **From 52-week high: -55.5%** (22.6% above the low). Trading 56% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 1.78** (volatility 77%). Beta of 1.78 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LXEO · Page: https://foliofundamentals.com/stocks/lxeo

Not investment advice.